With 1.08 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.12 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $1.88 whereas the lowest price it dropped to was $1.58. The 52-week range on BRTX shows that it touched its highest point at $2.55 and its lowest point at $1.21 during that stretch. It currently has a 1-year price target of $13.00. Beta for the stock currently stands at -0.52.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of BRTX was up-trending over the past week, with a rise of 21.14%, but this was up by 23.58% over a month. Three-month performance surged to 4.51% while six-month performance rose 12.90%. The stock gained 27.90% in the past year, while it has gained 8.87% so far this year. A look at the trailing 12-month EPS for BRTX yields -1.31 with Next year EPS estimates of -1.06. For the next quarter, that number is -0.36. This implies an EPS growth rate of -36.21% for this year and 32.59% for next year.
Float and Shares Shorts:
At present, 7.98 million BRTX shares are outstanding with a float of 5.77 million shares on hand for trading. On 2025-08-15, short shares totaled 0.15 million, which was 191.0 higher than short shares on 1752537600. In addition to Mr. Lance Alstodt as the firm’s Chairman of the Board, President & CEO, Mr. Robert Eugene Kristal serves as its Chief Financial Officer.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-06-30, BRTX reported revenue of $303300.0 and operating income of -$3305287.0. The EBITDA in the recently reported quarter was -$3827130.0 and diluted EPS was -$0.3.
Analysts Ratings:
In the same way, a target price assigned to a stock can also reveal much about its potential. With BRTX analysts setting a high price target of 18.0 and a low target of 8.0, the average target price over the next 12 months is 13.0. Based on these targets, BRTX could surge 883.61% to reach the target high and rise by 337.16% to reach the target low. Reaching the average price target will result in a growth of 610.38% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$1.23101 being high and -$1.58233 being low. For BRTX, this leads to a yearly average estimate of -$1.40667. The surprise factor in the prior quarter was -$0.32. Based on analyst estimates, the high estimate for the next quarter is -$0.28 and the low estimate is -$0.28. The average estimate for the next quarter is thus -$0.28.
